11/01/2017 21:22:00

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Related content
09 Mar - 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Remi..
08 Mar - 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Sharehold..
05 Mar - 
DEADLINE ALERT: Brower Piven Reminds Investors Of The M..

NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Western District of Washington on behalf of all those who purchased Seattle Genetics securities between October 27, 2016 and December 23, 2016 (the “Class Period”).  The case, Patel v. Seattle Genetics, Inc. et al, No. 2:17-cv-00041 was filed on January 10, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company’s experimental cancer drug, vadastuximab talirine, presents a significant risk of fatal hepatotoxicity; (ii) Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia treatment; and (iii) as a result, Seattle Genetics’ public statements were materially false and misleading.

Specifically, on December 27, 2016, Seattle Genetics announced that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine, to evaluate the potential risk of hepatotoxicity.  The Company stated, in part, that “six patients have been identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.”

After the announcement, Seattle Genetics’ share price fell from $61.86 per share on December 23, 2016 to a closing price of $52.36 on December 27, 2016—a $9.50 or a 15.36% drop.

Request more information now by clicking here: www.faruqilaw.com/SGEN. There is no cost or obligation to you.

Take Action

If you invested in Seattle Genetics stock or options between October 27, 2016 and December 23, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/SGEN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Seattle Genetics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP

685 Third Avenue, 26th Floor

New York, NY 10017

Attn: Richard Gonnello, Esq.

rgonnello@faruqilaw.com

Telephone: (877) 247-4292 or (212) 983-9330

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

HSBC Bank Plc : Form 8.5 (EPT/RI) - Redrow PLC

28/03/2017 10:41:26
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offe..

Alliance Trust PLC : Transaction in Own Shares

28/03/2017 00:07:35
28 March 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 27 March 2017 the Company purchased for cancellation 398,500 ordinary shares of 2.5p each at a price of 678.2761p per share.  Therefore, the total number of voting rights in the Company is now 364,854,566.    The above figure (364,854,566) may be used by sharehold..

Alliance Trust PLC : Annual Report and Accounts and AGM Notice

27/03/2017 15:03:02
Alliance Trust PLC ANNUAL REPORT AND ACCOUNTS AND AGM NOTICE Pursuant to Listing Rule 9.6.1, copies of the following documents have been submitted to the UK Listing Authority and will shortly be available for inspection via the National Storage Mechanism which is located at http://www.morningstar.co.uk/uk/NSM ·      Annual Report and Accounts ·      Results Summary and Notice of AGM The ab..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Invuity, Inc. (IVTY) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2
VivoPower International PLC Announces Substantial Completion and Partial Sale of 43 MW Solar Project in North Carolina
3
Alliance Trust PLC : Transaction in Own Shares
4
Griffin Capital Essential Asset REIT II Reports 2016 Results
5
Alliance Trust PLC : Annual Report and Accounts and AGM Notice

Related stock quotes

Seattle Genetics Inc 64.39 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 March 2017 12:53:58
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170324.2 - EUROWEB3 - 2017-03-28 13:53:58 - 2017-03-28 12:53:58 - 1000 - Website: OKAY